ETON

Eton Pharmaceuticals' stock has shown significant growth, gaining approximately 108% over the past six months and a 227.07% year-to-date return as of October 2026, though it decreased by 7.96% in the month leading up to September 2026. Key events include strong Q2 2026 financial performance with product sales surging 99% year-over-year to $37.6 million and EPS of $0.43, both exceeding estimates. Following these results, the company raised its 2026 revenue guidance to over $145 million with an anticipated adjusted EBITDA margin of at least 35%. Analyst sentiment is positive, with a "Moderate Buy" consensus and an average 12-month price target of $67.50. Insider trading activity included insiders selling a combined 75,000 shares in recent transactions. In September 2026, Eton relaunched IMPAVIDO in the U.S., enhancing patient support and specialty pharmacy access.